Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corixa Corporation and Lorantis have formed a joint collaboration to continue the development of a therapeutic hepatitis B vaccine, containing Corixa's RC-529 adjuvant and Lorantis' CV-1831, that was previously owned by Apovia.
Subscribe to our email newsletter
This collaboration builds on the initial R&D conducted by Corixa and Apovia for the development of a therapeutic vaccine for the treatment of hepatitis B. Lorantis has acquired all of Apovia’s interest in the hepatitis B vaccine technology and under the terms of the new agreement, Lorantis will assume many of Apovia’s development responsibilities.
The collaboration is managed by a joint management team, with Corixa taking the lead for the regulatory applications and management of all clinical trials. Lorantis will lead the completion of preclinical studies and supply the hepatitis B core antigen. The companies will share equally in all costs and potential revenues associated with the development of the vaccine.
Following proof-of-principle clinical trials, the companies intend to partner the vaccine to a late-stage development and commercialization organization.
“This partnership with Corixa should ensure that CV-1831 will be competitively developed,” said Stefan Fischer, CEO of Lorantis. “Our investment in this therapeutic hepatitis B vaccine is the first step to transform Lorantis from a research driven company into a development focused company as we build our immunology portfolio.”